HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
WEDNESDAY, Jan. 16 (HealthDay News) -- Duodenal infusions of donor feces are significantly more effective than vancomycin for treating recurrent Clostridium difficile infections, according to a study published online Jan. 16 in the New England Journal of Medicine.
Els van Nood, M.D., from the University of Amsterdam, and colleagues randomized patients with recurrent C. difficile infections to receive either vancomycin (500 mg orally four times per day for four days) followed by a bowel lavage and infusion of donor feces through a nasoduodenal tube; a standard vancomycin regimen (500 mg orally four times per day for 14 days); or a standard vancomycin regimen with bowel lavage.
The researchers stopped the study after interim analysis when it was determined that, after the first infusion, 13 of 16 patients in the infusion group had resolution of C. diffile-associated diarrhea. After a second infusion from a different donor, two additional patients had resolution. Resolution of infection was noted in four of 13 patients receiving vancomycin alone and in three of 13 patients receiving vancomycin and bowel lavage (P < 0.001 for comparisons with the infusion group). There were no significant between-group differences in adverse effects, although patients in the infusion group experienced mild diarrhea and abdominal cramping on the infusion day. Patients receiving the donor infusions exhibited increased fecal bacterial diversity similar to that seen in the healthy donors.
"In conclusion, in patients with recurrent C. difficile infection, the infusion of donor feces, as compared with vancomycin therapy, resulted in better treatment outcomes," the authors write. "In particular, patients with multiple relapses of C. difficile infection benefited from this unconventional approach."
Several authors disclosed financial ties to the pharmaceutical industry.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on June 04, 2022